Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer
Study Number: 

I 35316

Phase: 
1/2
Principal Investigator: 
Renuka Iyer, MD

Check your eligibility for this trial.

Official Title: 
A Phase Ib/ II Study of Sorafenib and Pembrolizumab in Advanced Hepatocellular Cancer (HCC)
Purpose: 
This phase Ib/II trial studies how well sorafenib tosylate and pembrolizumab work in treating patients with liver cancer that has spread to other parts of the body. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving sorafenib tosylate and pembrolizumab may work better in treating patients with liver cancer.
ClinicalTrials.Gov ID: 
NCT03211416
Learn more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-877-ROSWELL (1-877-767-9355) or e-mail askroswell@roswellpark.org.